Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia
Tumori Journal · 2025
DOI: 10.1177/03008916251346563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tumori Journal, 2025. Verfasst von Yan Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Leukemia, Myeloid, Acute, Glycine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Effect of IDH1 inhibitor combined with demethylation drugs on acute myeloid leukemia.
Abstract (Originalsprache)
Objective
Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in approximately 6-10% of acute myeloid leukemia (AML) patients. Ivosidenib (IVO) is a small-molecule inhibitor of mutant IDH1. This study delves into the mechanism of IVO with hypomethylating agents (HMAs) (azacitidine or decitabine) for treating IDH1-mutated AML through the PI3K/AKT pathway.
Methods
IDH1 R132H -mutated MOLM-13 (IDH1 R132H -MOLM-13) cells were constructed. The effects of the drugs, both individually and in combination, on IDH1 R132H -MOLM-13 cell proliferation and apoptosis were assessed using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide and flow cytometry, with combination index (CI) values calculated using CompuSyn software. IDH1 , DNMT1 , PI3K and AKT gene mRNA levels, and the PI3K/AKT pathway- and histone lysine methylation-related protein levels in IDH1 R132H -MOLM-13 cells were determined by RT-qPCR and Western blot.
Results
IDH1 R132H -mutated MOLM-13 cells (IDH1 R132H -MOLM-13) were successfully constructed. The IDH1 inhibitor, either as a monotherapy or combined with HMAs, effectively inhibited IDH1 R132H -MOLM-13 cell proliferation, and the combination therapy exhibited synergistic effects (CI < 1). The combination therapy increased cell proportion in the G2/M phase and apoptotic rate. Both treatment modalities reduced IDH1 , DNMT1 , PI3K and AKT mRNA levels and histone lysine methylation levels (H3K4me3, H3K9me3, H3K27me3); besides, PI3K and AKT phosphorylation levels were reduced, with the reductions being more significant in cells undergoing combination therapy. The indexes did not differ significantly between cells undergoing the two modalities of combined treatments.
Conclusion
The IDH1 inhibitor with HMAs suppressed IDH1 R132H -MOLM-13 cell proliferation and viability and decreased the methylation level by repressing the phosphorylation of the PI3K/AKT pathway, showing a synergistic inhibitory effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
ORCID-Profile: Yan Cheng
Förderung
- Effect of IDH1 inhibitor combined with demethylation drugs on acute myeloid leukemia
Zitieren
APA
Cheng, Y., & Wu, H. (2025). Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia. Tumori Journal. https://doi.org/10.1177/03008916251346563
Vancouver
Cheng Y, Wu H. Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia. Tumori Journal. 2025. doi:10.1177/03008916251346563
BibTeX
@article{Cheng2025,
author = {Cheng, Yan and Wu, Hongwei},
title = {Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia},
journal = {Tumori Journal},
year = {2025},
doi = {10.1177/03008916251346563}
}
EUVIMED